This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gutterman, D. D. Search for Related Content PubMed PubMed Citation Articles by Gutterman, D. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE NITROGLYCERIN Related Collections Cardiovascular Pharmacology Oxidant stress Endothelium/vascular type/nitric oxide Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1673.)
© 2007 American Heart Association, Inc.

Editorials

Combating Nitrate Tolerance

A Novel Endogenous Mechanism

David D. Gutterman

From the Departments of Medicine and Pharmacology, Medical College of Wisconsin and Zablocki VA Medical Center, Milwaukee.

Correspondence to David D. Gutterman, MD, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226. E-mail dgutt@mcw.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Discovered and patented as an explosive by Alfred Nobel in the 1860s, nitroglycerin has been formulated for use in the treatment of symptomatic CAD for over 140 years. In fact, later in life, Nobel himself was prescribed the medication for angina, but refused to take it because of the associated side effect of headache.

See page 1729

With glycerol trinitrate (GTN) as the prototype, nitrates represent one of the safest and most rapidly effective pharmacological means to reduce acute symptoms of myocardial ischemia attributable to obstructive coronary disease. This has led, over the years, to the development of long-acting oral and topical preparations. However, efficacy with chronic administration is more difficult to achieve because of the development of therapeutic resistance, generally occurring a few days after initiating treatment. This phenomenon known as nitrate tolerance has been the stimulus for intense investigation of the metabolic fate of nitroglycerin with the idea that modulation of its biotransformation could improve efficacy of chronic treatment.

The mechanism of GTN-induced dilation is complex and was not identified until more than 100 years after its discovery. GTN is not a direct vasodilator, rather it must be converted to dinitrate products for vasoactivity. Biotransformation to the active metabolite nitric oxide (NO) occurs in parallel with the formation of glycerol-1,2-dinitrate and involves a dithiol-dependent process.¹

It was not until recently that the principal enzyme responsible for biotransformation of GTN was identified. Chen et al¹ showed that mitochondrial aldehyde dehydrogenase (ALDH-2) metabolizes GTN to glycerol-1,2-dinitrate and nitrite. This was . . . [Full Text of this Article]

Related Article:

Heme Oxygenase-1: A Novel Key Player in the Development of Tolerance in Response to Organic Nitrates

Philip Wenzel, Matthias Oelze, Meike Coldewey, Marcus Hortmann, Andreas Seeling, Ulrich Hink, Hanke Mollnau, Dirk Stalleicken, Henry Weiner, Jochen Lehmann, Huige Li, Ulrich Förstermann, Thomas Münzel, and Andreas Daiber
Arterioscler Thromb Vasc Biol 2007 27: 1729-1735. [Abstract] [Full Text] [PDF]